Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Preventing Therapy Resistance in Esophageal Cancer Using Advanced Models and Molecular Signatures

Descripción del proyecto

Formación y tratamiento contra el cáncer de esófago

Se prevé que el cáncer se convierta en la principal causa de muerte en la Unión Europea de aquí a 2035. El cáncer de esófago se caracteriza por una alta resistencia y respuestas variables al tratamiento, por lo su desenlace clínicos suele ser malo. La ausencia de una estrategia unificada de bajo riesgo para esta afección contribuye a los resultados divergentes y a las desigualdades del cáncer en Europa. En el proyecto PRESSURE, financiado con fondos europeos, se pretende afrontar este reto formando a diez investigadores expertos en el desarrollo de tratamientos y políticas eficaces contra la resistencia al tratamiento del cáncer. El proyecto, que se centra en el adenocarcinoma de esófago, uno de los tipos de cáncer más complejos que requieren soluciones innovadoras, está en consonancia con Plan Europeo de Lucha contra el Cáncer. PRESSURE tiene por objeto proporcionar una amplia formación intersectorial a los investigadores, con la que adquirirán conocimientos exhaustivos sobre toda la cadena de valor del tratamiento del cáncer.

Objetivo

In 2035, cancer will have become the leading cause of death in the EU. In line with the Horizon Europe Plan to Beat Cancer, one of the five Horizon Missions, the PRESSURE network sets out to train 10 future experts who will push the development and clinical implementation of effective treatments and policies against therapy resistance in cancer. This innovative project will specifically focus on esophageal adenocarcinoma as one of the most complex cancer types in terms of resistance, and most urgently in need of novel solutions.

Prominent factors that contribute to the poor outcome of esophageal cancer are a high degree of acquired resistance, and heterogeneous responses to the available therapies. Despite this knowledge, there are currently no consensus treatments for this disease in the EU, and there is insufficient awareness of the need for a unified low-risk treatment strategy. Numerous different regimens are currently given across the continent, and as a result highly divergent outcomes of EAC are observed. This adds to Cancer Inequalities in Europe.

To address this, PRESSURE researchers will receive exhaustive intersectoral training, and deliver high-quality knowledge, across the entire value chain: Epidemiology, imaging, patient-derived model systems, resistance mechanisms, diagnostics, patient-centricity, valorization, and treatment. By receiving this diverse training, the ESRs will become next generation thinkers and problem-solvers, and will be able to deliver creative contributions to all fields involved in the combatting of cancer with unique solutions applicable in the clinic and society. This combination of complementary research expertise and rich training is not currently offered in an EU network.

Coordinador

STICHTING AMSTERDAM UMC
Aportación neta de la UEn
€ 823 111,20
Dirección
DE BOELELAAN 1117
1081 HV Amsterdam
Países Bajos

Ver en el mapa

Región
West-Nederland Noord-Holland Groot-Amsterdam
Tipo de actividad
Research Organisations
Enlaces
Coste total
Sin datos

Participantes (7)

Socios (12)